Mitochondria as a Source and a Target for Uremic Toxins

Abstract

Elucidation of molecular and cellular mechanisms of the uremic syndrome is a very challenging task. More than 130 substances are now considered to be “uremic toxins” and represent a very diverse group of molecules. The toxicity of these molecules affects many cellular processes, and expectably, some of them are able to disrupt mitochondrial functioning. However, mitochondria can be the source of uremic toxins as well, as the mitochondrion can be the site of complete synthesis of the toxin, whereas in some scenarios only some enzymes of the pathway of toxin synthesis are localized here. In this review, we discuss the role of mitochondria as both the target and source of pathological processes and toxic compounds during uremia. Our analysis revealed about 30 toxins closely related to mitochondria. Moreover, since mitochondria are key regulators of cellular redox homeostasis, their functioning might directly affect the production of uremic toxins, especially those that are products of oxidation or peroxidation of cellular components, such as aldehydes, advanced glycation end-products, advanced lipoxidation end-products, and reactive carbonyl species. Additionally, as a number of metabolic products can be degraded in the mitochondria, mitochondrial dysfunction would therefore be expected to cause accumulation of such toxins in the organism. Alternatively, many uremic toxins (both made with the participation of mitochondria, and originated from other sources including exogenous) are damaging to mitochondrial components, especially respiratory complexes. As a result, a positive feedback loop emerges, leading to the amplification of the accumulation of uremic solutes. Therefore, uremia leads to the appearance of mitochondria-damaging compounds, and consecutive mitochondrial damage causes a further rise of uremic toxins, whose synthesis is associated with mitochondria. All this makes mitochondrion an important player in the pathogenesis of uremia and draws attention to the possibility of reducing the pathological consequences of uremia by protecting mitochondria and reducing their role in the production of uremic toxins.

Empagliflozin restores chronic kidney disease–induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction

“…The uremic serum-induced increase in oxidative stress appears mainly mitochondria-derived and leads to NO scavenging. This is in line with other studies showing mitochondria as a source of oxidative stress upon uremic serum exposure, 45,46 which can lead to an increase in intracellular ROS and a reduction in NO level. 46,47 Superoxide is highly reactive and can rapidly react with NO to form peroxynitrite, which can cause damage, including nitration modification of the tyrosine residues of proteins, yielding 3NT, commonly used as a footprint of peroxynitrite formation.…”

Microbiome-Metabolome Signature of Acute Kidney Injury

“…Creatinine is a product of degradation of creatine phosphate [82], one of the main energy substrates in mitochondria [83]. Therefore, the correlation between the levels of these metabolites might reflect the involvement of mitochondria in metabolic changes after AKI, which was previously indicated for a number of uremic toxins [84].…”

Discovery and validation of an NMR-based metabolomic profile in urine as TB biomarker

“…In this metabolic process urea and other amino groups are synthesised from the breakdown of the amino acids. Thus, the low concentration of urine hippurate observed in TB patients might be due to/connected to the synthesis of aromatic amino acids such as tryptophan, tyrosine and phenylalanine 39 , 40 . Alternatively , Weiner et al suggested that low serum hippurate concentrations might be related to uremic cytotoxic activity related to vitamin D metabolism 24 .…”